Skip to main content

Flares Not Increased Following Recombinant Zoster Vaccine Injections

Jun 15, 2022 6:48 pm

Insurance claims analysis has shown that the use of the (CDC recommended) recombinant zoster vaccine (RZV) for prevention of herpes zoster (HZ) was highly used in patients with immune-mediated inflammatory diseases (IMIDs) and was safe, as higher rates of arthritis flares were not evident.

In 2018, CDC recommended the recombinant zoster vaccine (RZV) for HZ prevention in immunocompetent ≥50 years-olds. This study examined rates of RZV vaccination (adults ≥50 years) among IMIDs patients during 2018–2019 and sought to identify presumed flares (defined as hospitalization/emergency department visits, or steroid treatment).

Among IMID patients, between 15% (commercial) and 43% (Medicare) received ≥1-dose of RZV (77 - 85% completed 2 doses). Flares were seen in 10% and 13% prior to RZV vaccination and in 9% and 11–12% after RZV vaccination.  Thus no significant increase in flares following RZV administration was observed in IMID patients following RZV dose-1 or dose-2.

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.